Tripletail Wealth Management’s Lucid Diagnostics LUCD Stock Holding History

Tripletail Wealth Management’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$196K	Buy	+183,417	New	+$198K	0.23%	80

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Tripletail Wealth Management's LUCD Position: Q2 2026 in Review

Tripletail Wealth Management opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 183,417 shares worth $196K. The stake represents 0.23% of the portfolio and ranks #80 among its holdings.

116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Tripletail Wealth Management held 183,417 shares of Lucid Diagnostics worth $196K as of Q2 2026.
Lucid Diagnostics was a new Tripletail Wealth Management position in Q2 2026.
Lucid Diagnostics made up 0.23% of Tripletail Wealth Management's portfolio in Q2 2026, its #80 holding.
116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Tripletail Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.